- Home
- AQST
as 11-10-2025 2:27pm EST
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.
| Founded: | 2004 | Country: | United States |
| Employees: | N/A | City: | WARREN |
| Market Cap: | 809.3M | IPO Year: | 2018 |
| Target Price: | $10.00 | AVG Volume (30 days): | 3.0M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.70 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.12 - $7.55 | Next Earning Date: | 11-05-2025 |
| Revenue: | $43,397,000 | Revenue Growth: | -26.32% |
| Revenue Growth (this year): | -20.29% | Revenue Growth (next year): | 51.39% |
Stock Insider Trading Activity of Aquestive Therapeutics Inc. (AQST)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Boyd Peter E. | AQST | See Remarks | Oct 15 '25 | Sell | $7.00 | 10,000 | $70,000.00 | 268,323 | |
| Kraus Carl N | AQST | Chief Medical Officer | Oct 15 '25 | Sell | $7.00 | 20,272 | $141,904.00 | 282,475 | |
| Jung Cassie | AQST | Chief Operating Officer | Oct 15 '25 | Sell | $7.01 | 67,575 | $473,700.75 | 240,771 | |
| Barber Daniel | AQST | President and CEO | Sep 26 '25 | Sell | $6.03 | 91,343 | $551,191.06 | 923,430 | |
| Boyd Peter E. | AQST | See Remarks | Sep 26 '25 | Sell | $6.30 | 10,000 | $63,000.00 | 268,323 | |
| Barber Daniel | AQST | President and CEO | Sep 19 '25 | Sell | $6.00 | 400 | $2,400.00 | 923,430 | |
| Boyd Peter E. | AQST | See Remarks | Sep 5 '25 | Sell | $5.30 | 15,000 | $79,500.00 | 268,323 | |
| Jung Cassie | AQST | Chief Operating Officer | Sep 4 '25 | Sell | $5.00 | 62,180 | $310,900.00 | 240,771 |
Latest Aquestive Therapeutics Inc. News
AQST Breaking Stock News: Dive into AQST Ticker-Specific Updates for Smart Investing
Zacks
11 days ago
Is DBV Technologies (DBVT) Stock Outpacing Its Medical Peers This Year?
GlobeNewswire
12 days ago
Aquestive Therapeutics to Attend 2025 ACAAI Annual Meeting
GlobeNewswire
15 days ago
Aquestive Therapeutics to Report Third Quarter 2025 Financial Results and Recent Business Highlights on November 5 and Host Conference Call on November 6 at 8:00 a.m. ET
Zacks
a month ago
Aquestive Therapeutics (AQST) Surges 7.9%: Is This an Indication of Further Gains?
Simply Wall St.
a month ago
Watching the Narrative for Aquestive Therapeutics Shift After Key Anaphylm Milestones
MT Newswires
a month ago
Sector Update: Health Care Stocks Advance Late Afternoon
MT Newswires
a month ago
Sector Update: Health Care
MT Newswires
a month ago
Update: Aquestive Therapeutics Shares Rise After Obtaining 2 New US Patents for Anaphylm Sublingual Film
Compare AQST vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "AQST Aquestive Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.